EPRSQ
EPIRUS BIOPHARMS INC
stock OTC

epirus biopharmaceuticals (nasdaq:eprs) is a pure-play biosimilar company focused on the global development and commercialization of biosimilar monoclonal antibodies (mabs). epirus' goal is to improve global patient access to important, cost-effective medicines. the company's current pipeline of biosimilar product candidates includes: bow015 (infliximab, reference biologic remicade®) currently marketed outside the u.s. and in an ongoing global phase 3 study for registration in europe and north america; bow050 (adalimumab, reference biologic humira®); bow070 (tocilizumab, reference biologic actemra®); bow080 (eculizumab, reference biologic soliris®); bow090 (ustekinumab, reference biologic stelara®); and bow100 (golimumab, reference biologic simponi®). the reference products for these candidates together generated approximately $29.2 billion in global sales for 2014, according to evaluatepharma®. epirus has established multiple partnerships to support its regulatory and commercializatio